Welcome to our dedicated page for Fractyl Health SEC filings (Ticker: GUTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fractyl Health, Inc. filings document regulatory, financial, governance and capital-structure disclosures for a clinical-stage metabolic therapeutics company developing Revita® and the Rejuva® gene therapy platform. Form 8-K reports furnish operating results, corporate presentations, REMAIN-1 clinical updates, Revita regulatory communications, Rejuva clinical-trial authorization for RJVA-001, and other Regulation FD disclosures.
The filing record also includes proxy materials for annual-meeting governance and equity-compensation matters, common stock and warrant disclosures, including Tranche A Common Stock Purchase Warrants, and Nasdaq continued-listing compliance notices. These documents describe the company’s public-company reporting, capital structure, stockholder voting matters and development-stage corporate disclosures.
FRACTYL HEALTH, INC. director Ian Sheffield reported an open-market purchase and an option grant. He bought 35,000 shares of Common Stock at $0.7294 per share, giving him 35,000 shares held directly after the transaction.
He was also granted 22,500 stock options with an exercise price of $0.7318 per share, each for one share of Common Stock and expiring on June 9, 2036. The option vests in a single installment on the earlier of the next annual stockholder meeting or the first anniversary of the grant, subject to his continued service on the board as a non-employee director.
Fractyl Health, Inc. Chief Executive Officer Harith Rajagopalan reported an open-market purchase of 25,000 shares of common stock on June 10, 2026 at a weighted average price of $0.7301 per share, with trade prices ranging from $0.7213 to $0.7324.
Following this transaction, he directly holds 540,557 shares of common stock and indirectly holds additional shares through three trusts with reported positions of 18,639, 292,170, and 292,171 shares. His holdings also include 13,812 shares purchased under the company’s 2024 Employee Stock Purchase Plan on January 30, 2026 at $0.391 per share.
FRACTYL HEALTH, INC. Chief Financial Officer Lara Smith Weber reported an open-market purchase of 20,000 shares of common stock. The shares were bought on June 8, 2026 at a weighted average price of $0.6854 per share, in multiple trades between $0.6844 and $0.6896. Following this transaction, she directly owns 20,000 common shares.
Fractyl Health reported encouraging one-year results from its open-label REVEAL-1 Cohort evaluating the Revita procedure in people with obesity who stopped GLP-1 drugs after losing at least 15% of body weight. Participants had lost about 24% total body weight on GLP-1 therapy before enrollment.
After a single Revita procedure, patients retained roughly 78% of that GLP-1-induced weight loss at one year, with a mean total body weight change of 5.3% and 33% of participants continuing to lose weight. All patients maintained at least 5% of their prior weight loss.
Glycemic control was stable, with an HbA1c change of 0.08%, and there were no procedure-related serious adverse events. Mild treatment-emergent events occurred in 36% of participants, were transient, and appeared within the first month. Fractyl expects randomized REMAIN-1 data readouts in Q3 and early Q4 2026.
Fractyl Health, Inc. ownership disclosure: Nantahala Capital Management, LLC and its two managing members report beneficial ownership of 16,124,780 shares of Common Stock as of March 31, 2026, representing 9.99% of the class. The holdings include 2,760,261 shares that may be acquired within sixty days through the exercise of convertible securities. The filing states shared voting and dispositive power for Nantahala, Wilmot B. Harkey and Daniel Mack; sole voting and dispositive power are reported as zero.
683 Capital Management, 683 Capital Partners and Ari Zweiman report beneficial ownership in Fractyl Health, Inc. As of March 31, 2026 the filing shows 6,727,235 shares plus 952,380 currently exercisable warrants attributable to the Reporting Persons, totaling 7,679,615 shares, or 4.81% of the company's common stock based on 158,648,963 shares outstanding per the issuer's Form 10-K.
The Schedule 13G/A notes shared voting and dispositive power for the reported shares and lists the Reporting Persons' principal address. The filing is an amended beneficial-ownership disclosure reflecting holdings as of the stated dates.
Fractyl Health Inc received an amended Schedule 13G/A reporting that SilverArc Capital Management, LLC and Devesh Gandhi beneficially own 3,606,386 shares of Class A Common Stock, representing 2.3% of the class. The filing lists shared voting and dispositive power over those shares.
Fractyl Health, Inc. reported net income of $9.2 million for the three months ended March 31, 2026, mainly from a $30.1 million non-cash gain on warrant liabilities. Operating expenses were $20.8 million, and Adjusted EBITDA was a loss of $18.0 million, reflecting ongoing investment in Revita and Rejuva.
Cash and cash equivalents were $63.2 million, with management expecting funding to last into early 2027 but disclosing substantial doubt about the ability to continue as a going concern over 12 months from issuance. The company also received a Nasdaq notice for falling below the $1.00 minimum bid price. Clinical progress included midpoint Revita weight-maintenance data and Dutch authorization to begin a first‑in‑human Rejuva RJVA‑001 trial in type 2 diabetes.
Fractyl Health, Inc. reported first quarter 2026 results and reiterated key clinical and cash runway milestones. For the quarter ended March 31, 2026, the company posted net income of $9.2 million, compared with a net loss of $23.7 million a year earlier, mainly due to a $30.1 million non-cash gain from changes in the fair value of warrant liabilities.
Operating expenses fell to $20.8 million from $24.8 million, and Adjusted EBITDA was a loss of $18.0 million versus a loss of $23.1 million in 2025. Cash and cash equivalents were $63.2 million as of March 31, 2026, which the company believes will fund operations into early 2027.
Fractyl highlighted progress for its Revita procedural therapy and Rejuva gene therapy platform, including completion of randomization in the REMAIN-1 pivotal cohort, planned Revita data readouts through Q4 2026, and Clinical Trial Authorization in the Netherlands for first-in-human testing of RJVA-001 in type 2 diabetes in the second half of 2026.
Fractyl Health, Inc. announced that it received Clinical Trial Application authorization in the Netherlands to start a Phase 1/2 first-in-human study of RJVA-001, its lead Rejuva Smart GLP-1 gene therapy candidate for type 2 diabetes. This authorization makes Fractyl a dual clinical-stage company, with Revita in pivotal development for post-GLP-1 weight maintenance and Rejuva entering first-in-human testing.
The company expects to dose the first patient with RJVA-001 and report preliminary data in the second half of 2026, subject to site activation. Management states that Rejuva’s clinical development is funded within the existing cash runway into early 2027, beyond the anticipated REMAIN-1 pivotal data readout, with no change to capital plans.